✦ LIBER ✦

Age does not appear to be a barrier to aggressive therapy with paclitaxel and carboplatin in women with ovarian cancer

Book ID: 120871317
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2000
Weight: 151 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200012240-00044

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is Age a Barrier to the Aggressive Treat

Is Age a Barrier to the Aggressive Treatment of Ovarian Cancer with Paclitaxel and Carboplatin?

✍ Robert V. Higgins; R.Wendel Naumann; Joanne Gardner; James B. Hall 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 166 KB

A Phase II Study of the MDR Inhibitor Bi

A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy

✍ Michael V. Seiden; Kenneth D. Swenerton; Ursula Matulonis; Susan Campos; Peter R 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 88 KB

MDM2 SNP309 T>G alone or in combination

MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients

✍ Bente A. Talseth; Cliff Meldrum; Janina Suchy; Grzegroz Kurzawski; Jan Lubinski; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 64 KB 👁 1 views

## Abstract Disease expression in hereditary nonpolyposis colorectal cancer (HNPCC) cannot be readily explained by mutation site in the respective DNA mismatch repair genes associated with this disorder. One explanation is the role of modifying genes that can either promote or prevent disease devel